Table 1 Biodistribution of 125I-anti-TLR5 mAb in TLR5+ and TLR5− 4T1 tumor models group.

From: TLR5: A prognostic and monitoring indicator for triple-negative breast cancer

 

Time (h)

24

48

72

Blood

4.47 ± 0.55

2.87 ± 0.41

1.42 ± 0.12

Thyroid

2.28 ± 0.13

1.15 ± 0.31

1.46 ± 0.40

Heart

2.02 ± 0.32

1.63 ± 0.09

1.15 ± 0.12

Lung

5.00 ± 0.87

1.31 ± 0.31

1.23 ± 0.14

Liver

7.56 ± 0.71

2.91 ± 0.23

2.05 ± 0.12

Spleen

4.05 ± 0.99

0.86 ± 0.07

0.66 ± 0.11

Kidney

8.36 ± 1.02

3.02 ± 0.77

1.38 ± 0.20

Intestines

1.41 ± 0.20

0.54 ± 0.22

0.59 ± 0.37

Bone

0.85 ± 0.26

0.61 ± 0.15

0.29 ± 0.05

Muscle

1.20 ± 0.14

0.59 ± 0.11

0.37 ± 0.06

Tumor(TLR5+)

7.73 ± 0.75**

4.92 ± 0.36**

2.58 ± 0.18**

Tumor(TLR5−)

1.39 ± 0.10

0.70 ± 0.05

0.42 ± 0.03

  1. 125I radiolabeled sodium iodide, h hours
  2. **P < 0.01 compared to the TLR5+ 4T1 tumor and the TLR5− 4T1 tumor in the same mouse. Data are presented as a mean percent injected dose per gram (%ID/g) ± standard deviation (Mean ± SD) of five animals
Back to article page